Literature DB >> 2093368

Perioperative assessment of the quality of myocardial protection.

J N Fabiani1, V Jebara, A Carpentier.   

Abstract

Perioperative myocardial protection constitutes one of the major advances of modern cardiac surgery, but perioperative assessment of its quality is difficult in clinical practice. This review details our approach to myocardial protection in specific situations, as well as the techniques we use to assess it in three different settings: Is distribution of antegrade cardioplegia homogeneous in patients presenting coronary artery stenosis? The problem was to determine if cardioplegic solutions used antegradely or retrogradely could represent a reliable echographic contrast for myocardial imaging in coronary artery disease patients and normal coronary artery patients, and further if significant differences of myocardial contrast exist between the two methods. Does warm reperfusion cardioplegia improve postoperative myocardial function in patients with an ejection fraction (EF) less than 35%? Pre- and postoperative hemodynamic workup with construction of Starling curves were used to answer this question. Does reperfusion of ischemic hearts induce free radical formation in humans? Deleterious effects of reperfusion are usually determined by studying the effects of free radicals on the myocardium, by determining the concentrations of substances that reflect the degree of membrane phospholipid destruction. However, the specificity and the sensitivity of such assays are low. We recently described white cell chromosomal aberrations secondary to free radical formation, after ischemic and reperfusion injury. Values obtained are expressed as the percentage of the total number of chromosomes. Although specialized laboratory techniques are required, this test is highly accurate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2093368     DOI: 10.1007/BF00051277

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  9 in total

1.  Treatment of lymphocyte cultures with a hypoxanthine-xanthine oxidase system induces the formation of transferable clastogenic material.

Authors:  I Emerit; S H Khan; P A Cerutti
Journal:  J Free Radic Biol Med       Date:  1985

2.  Clastogenic factor in ischemia-reperfusion injury during open-heart surgery: protective effect of allopurinol.

Authors:  I Emerit; J N Fabiani; O Ponzio; A Murday; F Lunel; A Carpentier
Journal:  Ann Thorac Surg       Date:  1988-12       Impact factor: 4.330

Review 3.  Strategies and logic of cardioplegic delivery to prevent, avoid, and reverse ischemic and reperfusion damage.

Authors:  G D Buckberg
Journal:  J Thorac Cardiovasc Surg       Date:  1987-01       Impact factor: 5.209

4.  Cardiac valve surgery--the "French correction".

Authors:  A Carpentier
Journal:  J Thorac Cardiovasc Surg       Date:  1983-09       Impact factor: 5.209

Review 5.  Oxygen-derived free radicals in postischemic tissue injury.

Authors:  J M McCord
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

6.  Tumor promoter phorbol 12-myristate 13-acetate induces a clastogenic factor in human lymphocytes.

Authors:  I Emerit; P A Cerutti
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

7.  Myocardial distribution of retrograde flow through the coronary sinus of the excised normal canine heart.

Authors:  K Shiki; M Masuda; K Yonenaga; T Asou; K Tokunaga
Journal:  Ann Thorac Surg       Date:  1986-03       Impact factor: 4.330

8.  [Myocardial protection during ischemic cardiac arrest. Hemodynamic study of the effects of allopurinol in a cardioplegic solution].

Authors:  P Périer; J N Fabiani; M Bocher; H Massoud; A Carpentier; C Dubost
Journal:  Arch Mal Coeur Vaiss       Date:  1980-06

9.  Effect of perfusate temperature on myocardial protection from ischemia.

Authors:  G F Tyers; E H Williams; H C Hughes; G J Todd
Journal:  J Thorac Cardiovasc Surg       Date:  1977-05       Impact factor: 5.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.